Francisco P Branco1, Duarte Machado2, Filipa F Silva3, Saudade André4, Ana Catarino5, Rosa Madureira6, João M Pinto1, João P Godinho1, Pedro D Simões1, Margarida Brito2, Mafalda Casa-Nova1, António R Moreira2, José L Passos-Coelho1,3. 1. Hospital Beatriz Ângelo, Medical Oncology Av. Carlos Teixeira, 3, 2674-514, Loures, Portugal. 2. Instituto Português de Oncologia de Lisboa Francisco Gentil, Medical Oncology R. Prof. Lima Basto, 1099-023, Lisbon, Portugal. 3. Hospital da Luz, Medical Oncology Av. Lusíada 100, 1500-650 Lisbon, Portugal. 4. Instituto Português de Oncologia de Lisboa Francisco Gentil, Pathology and Laboratory Medicine R. Prof. Lima Basto, 1099-023, Lisbon, Portugal. 5. Hospital da Luz, Pathology Av. Lusíada 100, 1500-650, Lisbon, Portugal. 6. Hospital Beatriz Ângelo, Pathology Av. Carlos Teixeira, 3, 2674-514, Loures, Portugal.
Abstract
INTRODUCTION: HER2 overexpression/amplification occurs in 15-20% breast cancers (BC) and is associated with worse prognosis. The addition of anti-HER2 treatment to neoadjuvant chemotherapy significantly improves the pathological complete response (pCR) rate. Changes in HER2 status after neoadjuvant treatment (NAT) have been reported and may affect prognosis. The aim of this study was to assess the efficacy of NAT in patients with HER2+ BC and its influence on HER2 status and associated prognostic impact. METHODS: Retrospective chart review and pathologic evaluation of all consecutive patients with HER2+ BC (defined as IHC 3+ or IHC 2+ confirmed by SISH) submitted to NAT between 2010-2015 in three Portuguese Hospitals. RESULTS: One hundred eight female patients were included; 40 with stage II, 68 with stage III. Hormone receptors were positive in 70. pCR (ypT0/isN0) was achieved in 48 patients (44%). With a median follow-up of 52 months, there were 5 disease free survival (DFS) events among pCR patients and 19 among non-pCR (P = 0.02). Of the 60 patients with residual disease at surgery, 52 remained HER2+ and 8 (13%) lost HER2 overexpression/amplification. 5y-DFS and 5y-OS was 70% and 84%, respectively, for patients whose residual tumors remained HER2+, and 21% and 50% for patients whose residual tumors became HER2 negative (P = 0.02 and < 0.001). DISCUSSION: We confirmed the negative prognostic impact of NAT-induced HER2 loss on residual tumor leading to worse DFS and OS. Despite the retrospective design and small sample size, these results suggest that it is important to retest HER2 after NAT, to better refine patient outcome. AJTR
INTRODUCTION:HER2 overexpression/amplification occurs in 15-20% breast cancers (BC) and is associated with worse prognosis. The addition of anti-HER2 treatment to neoadjuvant chemotherapy significantly improves the pathological complete response (pCR) rate. Changes in HER2 status after neoadjuvant treatment (NAT) have been reported and may affect prognosis. The aim of this study was to assess the efficacy of NAT in patients with HER2+ BC and its influence on HER2 status and associated prognostic impact. METHODS: Retrospective chart review and pathologic evaluation of all consecutive patients with HER2+ BC (defined as IHC 3+ or IHC 2+ confirmed by SISH) submitted to NAT between 2010-2015 in three Portuguese Hospitals. RESULTS: One hundred eight female patients were included; 40 with stage II, 68 with stage III. Hormone receptors were positive in 70. pCR (ypT0/isN0) was achieved in 48 patients (44%). With a median follow-up of 52 months, there were 5 disease free survival (DFS) events among pCR patients and 19 among non-pCR (P = 0.02). Of the 60 patients with residual disease at surgery, 52 remained HER2+ and 8 (13%) lost HER2 overexpression/amplification. 5y-DFS and 5y-OS was 70% and 84%, respectively, for patients whose residual tumors remained HER2+, and 21% and 50% for patients whose residual tumors became HER2 negative (P = 0.02 and < 0.001). DISCUSSION: We confirmed the negative prognostic impact of NAT-induced HER2 loss on residual tumor leading to worse DFS and OS. Despite the retrospective design and small sample size, these results suggest that it is important to retest HER2 after NAT, to better refine patient outcome. AJTR
Authors: Valentina Guarneri; Kristine Broglio; Shu-Wan Kau; Massimo Cristofanilli; Aman U Buzdar; Vicente Valero; Thomas Buchholz; Funda Meric; Lavinia Middleton; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2006-03-01 Impact factor: 44.544
Authors: Emad A Rakha; Maysa E El-Sayed; Andrew R Green; E Claire Paish; Desmond G Powe; Julia Gee; Robert I Nicholson; Andrew H S Lee; John F R Robertson; Ian O Ellis Journal: J Clin Oncol Date: 2007-09-17 Impact factor: 44.544
Authors: Elizabeth A Mittendorf; Yun Wu; Maurizio Scaltriti; Funda Meric-Bernstam; Kelly K Hunt; Shaheenah Dawood; Francisco J Esteva; Aman U Buzdar; Huiqin Chen; Sameena Eksambi; Gabriel N Hortobagyi; Jose Baselga; Ana M Gonzalez-Angulo Journal: Clin Cancer Res Date: 2009-11-17 Impact factor: 12.531
Authors: N Niikura; A Tomotaki; H Miyata; T Iwamoto; M Kawai; K Anan; N Hayashi; K Aogi; T Ishida; H Masuoka; K Iijima; S Masuda; K Tsugawa; T Kinoshita; S Nakamura; Y Tokuda Journal: Ann Oncol Date: 2015-12-23 Impact factor: 32.976
Authors: Nathaniel W Mabe; Min Huang; Guillermo N Dalton; Gabriela Alexe; Daniel A Schaefer; Anna C Geraghty; Amanda L Robichaud; Amy S Conway; Delan Khalid; Marius M Mader; Julia A Belk; Kenneth N Ross; Michal Sheffer; Miles H Linde; Nghi Ly; Winnie Yao; Maria Caterina Rotiroti; Benjamin A H Smith; Marius Wernig; Carolyn R Bertozzi; Michelle Monje; Constantine S Mitsiades; Ravindra Majeti; Ansuman T Satpathy; Kimberly Stegmaier; Robbie G Majzner Journal: Nat Cancer Date: 2022-07-11
Authors: Adam L Maddox; Matthew S Brehove; Kiarash R Eliato; Andras Saftics; Eugenia Romano; Michael F Press; Joanne Mortimer; Veronica Jones; Daniel Schmolze; Victoria L Seewaldt; Tijana Jovanovic-Talisman Journal: Cancers (Basel) Date: 2022-06-04 Impact factor: 6.575
Authors: Gabriela Candás; Alejandra García; María Delfina Ocampo; Ernesto Korbenfeld; H Daniel Vuoto; Juan Isetta; Lucas Cogorno; Agustina González Zimmermann; Marca Sigal; Santiago Acevedo; Julia Berwart; Martín Naveira; Agustina Bemi; Juan Luis Uriburu Journal: Ecancermedicalscience Date: 2021-01-05
Authors: Sibylle Loibl; Chiun-Sheng Huang; Max S Mano; Eleftherios P Mamounas; Charles E Geyer; Michael Untch; Jean-Christophe Thery; Ingo Schwaner; Steven Limentani; Niklas Loman; Kristina Lübbe; Jenny C Chang; Thomas Hatschek; David Tesarowski; Chunyan Song; Sanne Lysbet de Haas; Thomas Boulet; Chiara Lambertini; Norman Wolmark Journal: NPJ Breast Cancer Date: 2022-09-19
Authors: Ayaka Katayama; Islam M Miligy; Sho Shiino; Michael S Toss; Karim Eldib; Sasagu Kurozumi; Cecily M Quinn; Nahla Badr; Ciara Murray; Elena Provenzano; Grace Callagy; Cian Martyn; Rebecca Millican-Slater; Colin Purdie; Dave Purnell; Sarah E Pinder; Tetsunari Oyama; Abeer M Shaaban; Ian Ellis; Andrew H S Lee; Emad A Rakha Journal: Mod Pathol Date: 2021-02-01 Impact factor: 7.842